FDA Hormone Therapy Outreach Will Stress Short-Term, Low-Dose Use
Executive Summary
FDA's hormone therapy outreach campaign will initially focus on encouraging short-term, low-dose use, Commissioner McClellan told the House Agriculture Appropriations Subcommittee March 6
You may also be interested in...
FDA Hormone Therapy Education Campaign Affirms Osteoporosis Use
FDA is not taking a position on the combination of "natural" products used in conjunction with hormone therapy in its consumer education campaign on hormone therapy launched Sept. 9
Berlex Yasmin 20 NDA Filing For Lower Estrogen Dose Slated For Q4
Schering AG's Berlex subsidiary will highlight Yasmin 20's lower estrogen dose and 24-day hormone treatment regimen in marketing the oral contraceptive
Berlex Yasmin 20 NDA Filing For Lower Estrogen Dose Slated For Q4
Schering AG's Berlex subsidiary will highlight Yasmin 20's lower estrogen dose and 24-day hormone treatment regimen in marketing the oral contraceptive